ArticleFuture oncology (London, England)2025

E-VIRTUE: a study of enfortumab vedotin with or without pembrolizumab in rare genitourinary tumors-design and rationale.

Elias B A Chandran et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.